“The South Korean government is moving to tighten access to injectable obesity medications, closing prescription loopholes and cracking down on overseas purchases amid misuse concerns. According to the Ministry of Food and Drug Safety on Wednesday, the ministry is working to designate glucagon-like peptide-1 obesity treatments as drugs of concern for abuse. Wegovy and Mounjaro, which have been selling rapidly in Korea, are included in the planned designation. These medications mimic the GLP-1 hor
Original story
Continue reading at Korea Herald National
www.koreaherald.com
Summary generated from the RSS feed of Korea Herald National. All article rights belong to the original publisher. Click through to read the full piece on www.koreaherald.com.
